此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults

2017年5月18日 更新者:GlaxoSmithKline

Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Adults

The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy adults aged 18 to 45 years in China.

研究概览

研究类型

介入性

注册 (实际的)

52

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Guangxi
      • Liucheng County、Guangxi、中国、545200
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female subject of Chinese origin, 18 years to 45 years inclusive of age at the time of the vaccination.
  • Written informed consent obtained from the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Female subjects of non-childbearing potential may be enrolled in the study.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of vaccination.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.
  • Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests.
  • Any clinically significant history of chronic gastrointestinal disease including uncorrected congenital malformation of gastrointestinal tract that would predispose for Intusussception.
  • Gastroenteritis within 7 days preceding the study vaccine or placebo administration.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination. Planned administration/ administration of a vaccine not foreseen by the study protocol within 14 days of the study vaccine or placebo and ending 14 days after.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
  • Administration of immunoglobulins and/ or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.
  • Acute disease at the time of enrolment.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
  • History of chronic alcohol consumption and/ or drug abuse.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂组
受试者将接受安慰剂。
口服,单剂量
实验性的:Rotarix Group
Subjects will receive Rotarix™.
口服,单剂量

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Occurrence of each solicited symptom
大体时间:Within the 8-day (Day 0 - Day 7) follow-up period after the vaccine dose
Within the 8-day (Day 0 - Day 7) follow-up period after the vaccine dose

次要结果测量

结果测量
大体时间
Occurrence of unsolicited adverse events
大体时间:Within 31 days (Day 0 - Day 30) after the vaccine dose
Within 31 days (Day 0 - Day 30) after the vaccine dose
Occurrence of serious adverse events
大体时间:Throughout the study period following the vaccine dose
Throughout the study period following the vaccine dose

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年3月1日

初级完成 (实际的)

2010年3月31日

研究完成 (实际的)

2010年3月31日

研究注册日期

首次提交

2010年7月13日

首先提交符合 QC 标准的

2010年7月13日

首次发布 (估计)

2010年7月14日

研究记录更新

最后更新发布 (实际的)

2017年5月19日

上次提交的符合 QC 标准的更新

2017年5月18日

最后验证

2017年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • 113545

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

研究数据/文件

  1. 个人参与者数据集
    信息标识符:113545
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  2. 研究协议
    信息标识符:113545
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  3. 数据集规范
    信息标识符:113545
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  4. 知情同意书
    信息标识符:113545
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  5. 临床研究报告
    信息标识符:113545
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  6. 统计分析计划
    信息标识符:113545
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅